Skip to main content

Table 2 Incidence of biomarkers

From: Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study

Biomarker

Overall

Grade III

Grade IV

p

n

181

56

125

–

MGMT (n tested)

94

31

63

0.037

 Methylated, n (%)

36 (38)

17 (55)

19 (30)

–

 Non-methylated, n (%)

58 (62)

14 (45)

44 (70)

–

1p19q co-deletion (n tested)

92

39

53

< 0.01

 Present, n (%)

17 (18)

16 (41)

1 (2)

–

 Absent, n (%)

75 (82)

23 (59)

52 (98)

–

IDH1 mutation (n tested)

102

23

79

0.074

 Present, n (%)

20 (20)

8 (35)

12 (15)

–

 Absent, n (%)

82 (80)

15 (65)

67 (85)

–

ATRX (n tested)

32

7

25

0.440

 ATRX loss, n (%)

2 (6)

0

2 (8)

–

 ATRX intact, n (%)

30 (94)

7 (100)

23 (92)

–

  1. MGMT O6-methylguanine-DNA-transferase; IDH1 isocitrate dehydrogenase 1; ATRX alpha-thalassemia/mental retardation syndrome X-linked. P-values were calculated from two-sided Chi-square statistics with Yates correction to compare the presence or absence of the specific biomarker in grade III versus grade IV gliomas
  2. Figures in boldface represent p values of less than 0.05